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automated program that measures intima media thickness (IMT) by radio-
frequency (“Quality intima media thickness in real-time), and the presence
of ateroma plaques was evaluated following Mannheim consensus. Pulse
wave velocity (PWV) was measured through Mobil o graph® dispositive.
We repeat vascular study 3 years later. IMT900 m and PWV 10m/s
were considered as pathological values. Statistical analysis were per-
formed using SPSS 22.0 program.
Results: 108 patients were included. Twelve patients excluded due to
high vascular risk [previous event and/or diabetes type II or type I with
target organ injury]. Repeated VOP measurement was only available in
49 patients. 64.2% of patients were women and the mean age was 54.2
(SD 1,3) years. Mean disease duration was 93.1 (SD 12.7) months and
mean DAS28 was 1.7 (SD 0.1). 22.4% of patients received glucocorti-
coids, 47.8% NSAIDs, 83.6% DMARDs and 37.3% biological drugs. Mean
BMI was 26.5 (SD 0.5) kg/m². 38.8%, 28.4% and 43.3% of patients
were smokers, hypertensive (11.9% on ARA2, 3% on IECA, 1.5% on cal-
cium channel blockers, 10.4% on combined treatment) and 43.3% dyslipi-
demic [most of them (38.8%) on statins]. Mean CRP and ESR were 6.2
(SD 0.4) mg/l and 9.9 (SD 1) mm/h, respectively. Mean SCORE was
1.06 (SD 0.1). Baseline, 23.9% of patients had atheromatous plaques,
and 13.4% and 20.4% had a pathological IMT or PWV, respectively.
Three years later, we detected new and/or atheromatous plaques rises in
19.4% of patients and PWV and IMT worsening in 10.2% and 1.5% of
patients, respectively. As per logistic regression analysis, high baseline
SCORE (16.9%), high systolic blood pressure (8.6%), GF-MDRD (8.2%),
fibrinogen (6.8%) and the presence of dyslipidemia were the factors that
most contributed to the progression of vascular damage, with independ-
ence of the therapeutic objective used for their treatment.
Conclusion: Progression of vascular damage is mainly related to CVRF
in patients with PsA, therefore it is essential to intervene on CVRF early.
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Background: Secukinumab was the IL-17 inhibitor licensed for use in
Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS). The aim of this
study was to evaluate the effectiveness and safety of Secukinumab in
our cohort of patients.
Objectives: In order to assess the effectiveness and safety of Secukinu-
mab, a retrospective analysis of patients treated with this drug in the
Northern Health and Social Care Trust was undertaken.
Methods: Retrospective data was collected from the Local Biologic data-
base. All patients who were on Secukinumab were selected. They were
divided into two arms, Psoriatic Arthritis and Ankylosing Spondylitis. From
this baseline disease severity was sought, baseline inflammatory markers
and patient cohort data was collected. Patients were seen routinely at three
monthly intervals and outcomes were collected up to a 12 month period.
From patient notes drug response and adverse effects were recorded.
Results: A total of 41 patients with psoriatic arthritis were treated with
Secukinumab over the 12-month period studied. Twenty-six patients were
female and fifteen were male, with ages ranging from 26 to 70. Only 12
of the patients were on concomitant methotrexate, all met the NICE start
criteria with required DAS 76 scores. Seven of the patients were biologic
naïve (17%) at commencement of drug.
Of all the patients who responded, most had some response by 3
months, and all had further response by six months.
Sixteen patients (39%) discontinued treatment due to no response, one
due to increasing shortness of breath, wheeze and rash, and one patient
developed colitis.
Other side effects were noted, which did not cause the drug to be dis-
continued. Five patients had rash and urticaria, three reported headaches.
Infections were fairly common, five patients had chest infections, four had
sinusitis and three had urinary tract infections. Four patients reported
thrush, one oral thrush and three vaginal.
A total of 18 patients with Ankylosing Spondylitis were commenced on
Secukinumab. 11 males and 7 females. A third (6/18) were biologic
naïve. Ages ranged from 27 to 65.
In the first three months of commencement there was a reduction in
BADSAI scores of all patients. This remained at six months. Inflammatory
markers CRP and ESR were also reduced.
Seven patients discontinued Secukinumab after six months due to side
effects or lack or perceived response by the patient (seen in 1 patient).
Two patients had a loss of efficacy. The remaining four patients noted
cutaneous skin infections, sinus symptoms or headaches as noted in the
PsA arm of the audit.
Conclusion: Patients in the Northern Trust starting Secukinumab generally
have severe disease and most have had prior treatment with biologics.
There was a high incidence of non responders in this group, however in
those patients who responded there was a good response rate at 3
months, and these patients were still on treatment at 12 months. Side
effects were as expected, with infections being the most commonly
reported side effect.
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Background: PsA is a chronic musculoskeletal disease. The prevalence
of axial involvement in PsA varies according to the duration of the dis-
ease. In early stage the incidence varies between 5% and 28%, but it
increases up to 25-70% in later stages of the disease. In the literature,
there is limited data on the differences in disease activity, functional sta-
tus and quality of life of men and women with axial PsA.
Objectives: In this study, we aimed to evaluate the effect of gender dif-
ference on clinical findings, disease activity, functional status and quality
of life in patients with axial involvement in Turkey.
Methods: Patients with PsA who met the CASPAR classification criteria
were enrolled consequently in this cohort. Turkish League Against Rheu-
matism (TLAR)- Network was formed with the participation of 25 centers.
The demographic variables, fatigue, diagnostic delay, the beginning of
peripheral arthritis, enthesitis, dactylitis and spine involvement, inflamma-
tory lumbar pain, patients‘ quality of life, BASFI, HAQ, HAQ-s,VAS pain,
anxiety, depression and disease activity parameters (TJC, SJC, ESH,
DAS28, BASDAI), were recorded. Student’s t test and Chi-square test
were used to compare variables in SPSS v.22 program.
Results: A total of 1130 patients (36.0% male, 64.0% female) with PsA
included in this study. In this cohort, 169 male (46 ± 12.29) and 251
female (47.4 ± 12.11) had axial involvement. VAS pain (p <0.001),
fatigue (p <0.001), ESR (p <0.001), DAS28 (p <0.001), BASDAI score (p
<0.001), PsAQoL (p <0.001), HAQ score (p <0.001), HAQ-S score (p
<0.001), anxiety (p <0.001), depression (p <0.020), FACIT (p <0.001) and
FIRST (p <0.001) scores were statistically significantly worse in women
than males with axial PsA (Table 1). However, SF-36 physical component
score (p <0.001), SF-36 mental component score (p <0.001) and PASI
score (p <0.005) were statistically worse in male patients than in female
patients with axial involvement.
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Conclusion: This study shown that the burden of disease in axial PsA
has a significantly different between genders. Female patients with PsA
who have axial involvement have higher disease activity, physical disabil-
ity, functional limitation and higher depression and anxiety risk than male
patients. Therefore, we suggest that new strategies should be developed
for more effective treatment of axial PsA in female patients.
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Background: Nail psoriasis (PsO) is present in up to 80% in psoriatic
arthritis (PsA) patients (pts) and associated with significant pain, psycho-
social disability, decreased physical function and quality of life (QoL).1
Nail PsO is considered as one of the six core PsA domains by
GRAPPA2 and is a predictor of severe disease with joint involvement
and structural damage. Secukinumab (SEC) has demonstrated efficacy for
pts with nail PsO in the TRANSFIGURE study3 and significant improve-
ment in signs and symptoms of PsA in the FUTURE 5 study4
Objectives: To evaluate the efficacy of SEC on nail PsO and other fac-
ets of disease in the nail subset from the FUTURE 5 study through 52
weeks (wks).
Methods: Pts (N=996) with active PsA, were randomised to subcutaneous
SEC 300 mg loading dosage (LD; 300 mg), 150 mg LD (150 mg), 150
mg no LD or placebo (PBO). All groups received SEC or PBO at base-
line (BL), Wks 1, 2, 3, and 4, and then every 4 wks. Efficacy assess-
ments through Wk 52 included mNAPSI, ACR, PASI, HAQ-DI, SF-36
PCS, PsAQoL and resolution of dactylitis and enthesitis. Analyses through
Wk 16 used non-responder imputation (NRI) for binary and mixed-effect
model repeated measure (MMRM) for continuous variables. Observed
data are presented from Wk 20-52.
Results: A total of 663/996 (66.6%) PsA pts had concomitant nail PsO
at BL. Demographics and BL disease characteristics were balanced
between treatment groups in the nail subset, which were comparable with
overall population. The total mean mNAPSI score at BL was 16.4. SEC
300 and 150 mg doses improved nail PsO vs. placebo (PBO) at Wk 8,
12 and 16 (P < 0.0001), with further improvements through Wk 52 (Fig-
ure). ACR20/50 and PASI 90 responses, resolution of dactylitis and
enthesitis, physical function and QoL were also improved with SEC vs.
PBO at Wk 16 with sustained improvements through 52 wks (Table).
Conclusion: Secukinumab provided sustained improvements in nail dis-
ease, signs and symptoms of PsA, physical function and QoL through 52
wks in pts with PsA and moderate to severe nail PsO.
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Table. Summary of results
SEC PBO
N=231



















PASI 901,2 16 52.0* 36.8* 31.0* 7.6
52 62.3 (69) 50.7 (75) 49.3 (75) -
HAQ-DI3 16 -0.6* -0.5* -0.5* -0.2
52 -0.6 (132) -0.6 (117) -0.6 (136) -
SF-36 PCS3 16 7.82* 6.90* 6.00* 2.29
52 8.0 (134) 6.71
(123)
7.93 (137) -
PsAQoL3 16 -3.6* -3.6* -3.0† -1.1
52 -3.9 (134) -4.2 (122) -3.8 (137) -
Resolution of enthesitis,%4 16 58.2† 56.8† 47.2‡ 34.3
52 81.5 (92) 68.7 (80) 70.7 (82) -
Resolution of dactylitis,%4 16 63.8† 52.6‡ 59.2† 32.4
52 78.8 (52) 79.6 (49) 80.3 (66) -
*P<0.0001; †P<0.001; $P<0.01; ‡P<0.05 vs. PBO. NRI data for binary and MMRM data for
continuous variables presented at Wk 16. Observed data presented at Wk 52.
1% responders (n); 2Data from pts with BL psoriasis3% BSA: N=75 [300 mg]; 87
[150 mg], 84 [150 mg no LD] and 118 [PBO]; 3Mean change from baseline (n);
4Data from pts with enthesitis/dactylitis at BL: N=98/58 [300 mg]; 88/57 [150 mg],
89/76 [150 mg no LD] and 140/102 [PBO]; N, number of pts with nail PsO in each
group; n, number of evaluable pts at Wk 52
Disclosure of Interests: Peter Nash Grant/research support from: AbbVie,
Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche,
Sanofi, UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Jans-
sen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie,
Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche,
Sanofi, UCB, Philip J Mease Grant/research support from: AbbVie,
Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB,
Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc.,
Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie,
Scientific Abstracts Friday, 14 June 2019 921
copyright.











is: first published as 10.1136/annrheum
dis-2019-eular.8305 on 27 June 2019. D
ow
nloaded from
 
